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The pharmaceutical industry is one of the fastest
growing sectors in terms of its size and revenue
and has continued to exercise its tremendous sphere
of influence as long as mankind continues to exist.
Despite of this apparent certainty, the industry is
facing an unprecedented level of challenges like,
waning pipelines, looming patent expiries, increased
generic competition, stringent regulations, amplified
development costs, and slashed public-health care
budgets etc., which are threatening to crumble
even the largest pharmaceutical multinationals.
To accommodate these dynamic challenges, the
pharmaceutical industry is retooling their research
efforts constantly by adopting new drug delivery
systems in order to rescue failed compounds due
to their poor biopharmaceutical properties, and to
extend patents through innovative repositioning
and reformulation.
In the purview of such needs, colloidal drug delivery
systems in the last few decades have provided the
pharmaceutical industry with alternative formulation
approaches for difficult to design compounds.
Various colloids including nanoparticles, polymeric
micelles, lipid-based deliveries (liposomes, solid lipid
nanoparticles, proliposomes and microemulsion)
have been developed as carriers for encapsulation
of both hydrophilic and hydrophobic drugs (Boyd,
2008; Mitragotri and Vanbever, 2011).
Out of the aforementioned drug delivery systems,
drug delivery using lipid-based colloidal carriers
is an exciting domain that assists to resolve
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problems associated with the unsatisfactory
therapeutic response of various pharmaceutically
challenging molecules. Lipid-based drug delivery
is an emerging area of nanotechnology. This is an
innovative and powerful tool, which addresses many
delivery related issues of candidates possessing
poor biopharmaceutical properties. In the similar
way, lipid-based oral deliveries have evolved by
addressing several key issues like poor solubility,
rapid metabolism, positive food effect, low and erratic
bioavailability that are common consequences faced
during drug discovery program (Thomas et al., 2006;
Christopher et al., 2007; Beija et al. 2012). This is
now a maturing field. It’s unique attractiveness lies
with its biocompatibility, physicochemical properties
and their clear benefits related to the improvement
of biopharmaceutical properties of challenging
molecules (Mehnert and Mader, 2001; Chakraborty
et al., 2009). The colloidal lipid deliveries have proven
to enhance the permeability, intestinal solubility and
also reduce gastrointestinal (GI) transit times and
thereby increase dissolution of the encapsulated
active present within them. Furthermore, substantial
amount of research in literature suggests that the
compounds incorporated within these submicron
particles transit via systemic circulation through
lymphatic transport mechanisms. Consequently,
this overall process helps compounds to bypass the
first-pass metabolism and thus assist in improved
bioavailability (Porter and Charman, 2001; Hauss,
2007).
Liposomal formulations are the most widely
researched lipid-based deliveries. Liposomes
delivered through oral route may help to enhance
lipophilicity as well as absorption of poorly soluble
drugs through the GI tract (Chiang and Weiner
et al., 1987). However, liposomes suffer GI and
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